PMID- 18473778
OWN - NLM
STAT- MEDLINE
DCOM- 20080731
LR  - 20191110
IS  - 1871-5257 (Print)
IS  - 1871-5257 (Linking)
VI  - 6
IP  - 2
DP  - 2008 Apr
TI  - Antithrombotic agents for acute coronary syndromes.
PG  - 130-41
AB  - Current evidence suggests a central role for antithrombotic agents such as 
      unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the 
      management of acute coronary syndromes (ACS). In patients with acute myocardial 
      infarction, several studies have shown that LMWHs may represent an effective 
      alternative to UFH as an adjunct to thrombolytic therapy and are not associated 
      with an increased risk of major bleeding. In patients with unstable angina or 
      non-ST-segment elevation myocardial infarction, trials have shown that the LMWH 
      enoxaparin significantly reduces the risk of cardiovascular events, compared with 
      UFH, while other trials have shown that the combination of enoxaparin and a 
      glycoprotein IIb/IIIa antagonist is not associated with an excess risk of 
      bleeding. However, LMWHs are significantly more expensive that UFH. Recently, 
      newer antithrombotic agents such as fondaparinux and bivalirudin have shown 
      equivalent efficacy to the heparins with less bleeding and appear clinically 
      attractive. This review examines the current evidence for the efficacy and safety 
      of antithrombotic agents in ACS.
FAU - Mukherjee, Debabrata
AU  - Mukherjee D
AD  - Gill Heart Institute, Division of Cardiovascular Medicine, University of 
      Kentucky, 900 S. Limestone Street, 326 Wethington Building, Lexington, KY 
      40536-0200, USA. Mukherjee@uky.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cardiovasc Hematol Agents Med Chem
JT  - Cardiovascular & hematological agents in medicinal chemistry
JID - 101266881
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Clinical Trials as Topic/statistics & numerical data
MH  - Drug Design
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Treatment Outcome
RF  - 37
EDAT- 2008/05/14 09:00
MHDA- 2008/08/01 09:00
CRDT- 2008/05/14 09:00
PHST- 2008/05/14 09:00 [pubmed]
PHST- 2008/08/01 09:00 [medline]
PHST- 2008/05/14 09:00 [entrez]
AID - 10.2174/187152508783955042 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Agents Med Chem. 2008 Apr;6(2):130-41. doi: 
      10.2174/187152508783955042.